Report cover image

Global Gene Therapies for Tumor Treatment Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 191 Pages
SKU # APRC20556952

Description

Summary

According to APO Research, the global Gene Therapies for Tumor Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Gene Therapies for Tumor Treatment market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Gene Therapies for Tumor Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Gene Therapies for Tumor Treatment market include Shanghai Sunway, Novartis, Amgen, Sibiono and Gilead Sciences, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Gene Therapies for Tumor Treatment, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Gene Therapies for Tumor Treatment, also provides the value of main regions and countries. Of the upcoming market potential for Gene Therapies for Tumor Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Therapies for Tumor Treatment revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Gene Therapies for Tumor Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Gene Therapies for Tumor Treatment company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Gene Therapies for Tumor Treatment Segment by Company

Shanghai Sunway
Novartis
Amgen
Sibiono
Gilead Sciences
Gene Therapies for Tumor Treatment Segment by Type

Oncolytic Virotherapy
Gene Transfer
Gene Induced Immunotherapy
Gene Therapies for Tumor Treatment Segment by Application

Hospital
Clinic
Other
Gene Therapies for Tumor Treatment Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Gene Therapies for Tumor Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Gene Therapies for Tumor Treatment key companies, revenue, market share, and recent developments.
3. To split the Gene Therapies for Tumor Treatment breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Gene Therapies for Tumor Treatment market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gene Therapies for Tumor Treatment significant trends, drivers, influence factors in global and regions.
6. To analyze Gene Therapies for Tumor Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapies for Tumor Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapies for Tumor Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapies for Tumor Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Therapies for Tumor Treatment industry.
Chapter 3: Detailed analysis of Gene Therapies for Tumor Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Gene Therapies for Tumor Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Gene Therapies for Tumor Treatment in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Gene Therapies for Tumor Treatment Market Size, 2020 VS 2024 VS 2031
1.3 Global Gene Therapies for Tumor Treatment Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Gene Therapies for Tumor Treatment Market Dynamics
2.1 Gene Therapies for Tumor Treatment Industry Trends
2.2 Gene Therapies for Tumor Treatment Industry Drivers
2.3 Gene Therapies for Tumor Treatment Industry Opportunities and Challenges
2.4 Gene Therapies for Tumor Treatment Industry Restraints
3 Gene Therapies for Tumor Treatment Market by Company
3.1 Global Gene Therapies for Tumor Treatment Company Revenue Ranking in 2024
3.2 Global Gene Therapies for Tumor Treatment Revenue by Company (2020-2025)
3.3 Global Gene Therapies for Tumor Treatment Company Ranking (2023-2025)
3.4 Global Gene Therapies for Tumor Treatment Company Manufacturing Base and Headquarters
3.5 Global Gene Therapies for Tumor Treatment Company Product Type and Application
3.6 Global Gene Therapies for Tumor Treatment Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Gene Therapies for Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Gene Therapies for Tumor Treatment Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Gene Therapies for Tumor Treatment Market by Type
4.1 Gene Therapies for Tumor Treatment Type Introduction
4.1.1 Oncolytic Virotherapy
4.1.2 Gene Transfer
4.1.3 Gene Induced Immunotherapy
4.2 Global Gene Therapies for Tumor Treatment Sales Value by Type
4.2.1 Global Gene Therapies for Tumor Treatment Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Gene Therapies for Tumor Treatment Sales Value by Type (2020-2031)
4.2.3 Global Gene Therapies for Tumor Treatment Sales Value Share by Type (2020-2031)
5 Gene Therapies for Tumor Treatment Market by Application
5.1 Gene Therapies for Tumor Treatment Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global Gene Therapies for Tumor Treatment Sales Value by Application
5.2.1 Global Gene Therapies for Tumor Treatment Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Gene Therapies for Tumor Treatment Sales Value by Application (2020-2031)
5.2.3 Global Gene Therapies for Tumor Treatment Sales Value Share by Application (2020-2031)
6 Gene Therapies for Tumor Treatment Regional Value Analysis
6.1 Global Gene Therapies for Tumor Treatment Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Gene Therapies for Tumor Treatment Sales Value by Region (2020-2031)
6.2.1 Global Gene Therapies for Tumor Treatment Sales Value by Region: 2020-2025
6.2.2 Global Gene Therapies for Tumor Treatment Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Gene Therapies for Tumor Treatment Sales Value (2020-2031)
6.3.2 North America Gene Therapies for Tumor Treatment Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Gene Therapies for Tumor Treatment Sales Value (2020-2031)
6.4.2 Europe Gene Therapies for Tumor Treatment Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Gene Therapies for Tumor Treatment Sales Value (2020-2031)
6.5.2 Asia-Pacific Gene Therapies for Tumor Treatment Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Gene Therapies for Tumor Treatment Sales Value (2020-2031)
6.6.2 South America Gene Therapies for Tumor Treatment Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Gene Therapies for Tumor Treatment Sales Value (2020-2031)
6.7.2 Middle East & Africa Gene Therapies for Tumor Treatment Sales Value Share by Country, 2024 VS 2031
7 Gene Therapies for Tumor Treatment Country-level Value Analysis
7.1 Global Gene Therapies for Tumor Treatment Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Gene Therapies for Tumor Treatment Sales Value by Country (2020-2031)
7.2.1 Global Gene Therapies for Tumor Treatment Sales Value by Country (2020-2025)
7.2.2 Global Gene Therapies for Tumor Treatment Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.3.2 USA Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.4.2 Canada Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.6.2 Germany Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.7.2 France Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.7.3 France Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.9.2 Italy Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.10.2 Spain Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.11.2 Russia Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.14.2 China Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.14.3 China Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.15.2 Japan Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.17.2 India Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.17.3 India Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.18.2 Australia Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.22.2 Chile Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.24.2 Peru Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.26.2 Israel Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.27.2 UAE Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.29.2 Iran Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Gene Therapies for Tumor Treatment Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Gene Therapies for Tumor Treatment Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Gene Therapies for Tumor Treatment Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Shanghai Sunway
8.1.1 Shanghai Sunway Comapny Information
8.1.2 Shanghai Sunway Business Overview
8.1.3 Shanghai Sunway Gene Therapies for Tumor Treatment Revenue and Gross Margin (2020-2025)
8.1.4 Shanghai Sunway Gene Therapies for Tumor Treatment Product Portfolio
8.1.5 Shanghai Sunway Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Gene Therapies for Tumor Treatment Revenue and Gross Margin (2020-2025)
8.2.4 Novartis Gene Therapies for Tumor Treatment Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Amgen
8.3.1 Amgen Comapny Information
8.3.2 Amgen Business Overview
8.3.3 Amgen Gene Therapies for Tumor Treatment Revenue and Gross Margin (2020-2025)
8.3.4 Amgen Gene Therapies for Tumor Treatment Product Portfolio
8.3.5 Amgen Recent Developments
8.4 Sibiono
8.4.1 Sibiono Comapny Information
8.4.2 Sibiono Business Overview
8.4.3 Sibiono Gene Therapies for Tumor Treatment Revenue and Gross Margin (2020-2025)
8.4.4 Sibiono Gene Therapies for Tumor Treatment Product Portfolio
8.4.5 Sibiono Recent Developments
8.5 Gilead Sciences
8.5.1 Gilead Sciences Comapny Information
8.5.2 Gilead Sciences Business Overview
8.5.3 Gilead Sciences Gene Therapies for Tumor Treatment Revenue and Gross Margin (2020-2025)
8.5.4 Gilead Sciences Gene Therapies for Tumor Treatment Product Portfolio
8.5.5 Gilead Sciences Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.